ACEA Therapeutics

ACEA Therapeutics, oo ku taal San Diego, California waa shirkad la iska leeyahay oo dhan ee Sorrento. ACEA Therapeutics waxaa ka go'an in ay horumariso oo ay bixiso daaweyn cusub si loo horumariyo nolosha bukaanada qaba cudurrada nafta halis geliya.

Xaruntayada rasaasta, Abivertinib, oo ah inhibitor kinase yar oo molecule, ayaa hadda waxaa dib u eegis ku samaynaysa Maamulka Cuntada iyo Dawooyinka ee Shiinaha (CFDA) ee loogu talagalay daawaynta bukaanada qaba kansarka sanbabada unugyada yaryar (NSCLC) oo ay ku jiraan isbeddelka EGFR T790M. Waxa kale oo ay ku jirtaa tijaabooyin caafimaad oo lagu daweynayo bukaannada cusbitaalka la dhigay ee qaba Covid-19 ee Brazil iyo Maraykanka oo uu hoggaamiyo Sorrento Therapeutics. Xakameeyaha molecule kinase ee labaad ee ACEA, AC0058, wuxuu galay horumarka Wajiga 1B ee Maraykanka ee daaweynta lupus erythematosus (SLE).

Iyada oo ay weheliso urur R&D adag, ACEA waxa ay Shiinaha ka hirgalisay soo saarista dawooyinka iyo awoodaha ganacsi si ay u taageerto kobacayada muddada-dheer. Kaabayaashan ayaa ina siinaya kontorool weyn oo ku saabsan silsilada saadka si aan u hubinno in badeecada la geynayo bukaanka waqtigii loogu talagalay.

SCILEX

SCILEX HOLDING COMPANY ("Scilex"), oo ah shirkad inta badan lahaanshaha leh ee Sorrento, waxay u heellan tahay horumarinta iyo ganacsiga alaabada maareynta xanuunka. ZTlido waxay ku saleysantahay Maraykanka^® (nidaamka jirka la mariyo ee lidocaine 1.8%), waa dawada lidocaine ee daawada laguu qoray oo ay ansixisay Maamulka Cuntada iyo Dawooyinka ee Maraykanka si loo yareeyo xanuunka la xidhiidha Neuralgia Post-Herpetic (PHN), kaas oo ah nooc ka mid ah xanuunka dareemaha shingles ka dib.

Scilex's SP-102 (10 mg dexamethasone sodium phosphate gel), ama SEMDEXA™, ee daawaynta Lumbar Radicular Pain waxay ku jirtaa habka dhamaystirka tijaabada kiliinikada ee Wajiga III. Shirkaddu waxay filaysaa SP-102 inay noqoto duritaanka ugu horreeya ee FDA-da ee aan-opioid-ka ahayn ee lagu duro si loo daaweeyo xanuunka lumbosacral radicular pain, ama sciatica, iyada oo suurtagal ah in lagu beddelo 10 ilaa 11 milyan oo ka baxsan calaamadda cirbadaha steroids epidural-ka ee lagu maamulo sannad kasta gudaha Maraykanka.

Bioserver

Bioserv, oo ku taal San Diego, California waa shirkad la iska leeyahay oo dhan ee Sorrento. La aasaasay 1988, ururku waa adeeg bixiye wax soo saar qandaraas cGMP ah oo leh in ka badan 35,000 cagood oo laba jibbaaran oo tas-hiilaad ah kuwaas oo awooddooda udub dhexaad u tahay habaynta bulk iyo aseptic; sifaynta; buuxinta; joojinta; adeegyada lyophilization; calaamadaynta; alaabta la dhammeeyey; xirmooyinka iyo baakadaha; iyo sidoo kale kaydinta heerkulka la kontoroolo iyo adeegyada qaybinta si ay u taageeraan Pre-Clinical, Wajiga I iyo II Alaabooyinka Tijaabada Dawooyinka, qalabka daawada reagents, reagents iyo qalabyada baadhista caafimaadka, iyo reageyaasha sayniska nolosha.

Concortis-Levena

Sannadkii 2008, Concortis Biosystems waxaa la aasaasay iyada oo ujeedadu tahay in si wanagsan loogu adeego bulshada sayniska iyo dawada leh reagents iyo adeegyo tayo sare leh oo ka hortag ah conjugate daroogada (ADC). Sannadkii 2013, Sorrento waxa ay heshay Concortis, isaga oo abuuray shirkad ADC heer sare ah. Isku-darka G-MAB ™ (maktabariga si buuxda uga hortaga jidhka bini'aadamka) iyo Concortis sunta iska leh, isku xidhayaasha, iyo hababka isku xidhka ayaa awood u leh inay abuuraan hogaaminta warshadaha, ADCs jiilka 3aad.

Concortis waxa ay hadda sahamisaa in ka badan 20 kala duwan oo kala doorasho ADC ah (kiliinikada hore) iyada oo la adeegsanayo codsiyada oncology iyo wixii ka dambeeya. Oktoobar 19, 2015, Sorrento wuxuu ku dhawaaqay abuurista Levena Biopharma oo ah hay'ad madax-bannaan si ay u bixiso suuqa adeegyo kala duwan oo ADC ah laga bilaabo bilawga mashruuca ADC iyada oo loo marayo soosaarka cGMP ee ADC-yada illaa heerka I / II daraasadaha kiliinikada. Macluumaad faahfaahsan, fadlan booqo www.levenabiopharma.com

Hal qayb oo ka mid ah SmartPharm Therapeutics, Inc

SmartPharm Therapeutics, Inc. ("SmartPharm"), waa shirkad si buuxda loo leeyahay. Sorrento Therapeutics, Inc. (Nasdaq: SRNE), waa marxalad horumarineed shirkad biopharmaceutical ah oo diiradda saareysa jiilka soo socda, daawaynta hidda-wadaha aan fayraska ahayn ee loogu talagalay daaweynta cudurrada halista ah ama naadir ah oo leh aragti abuurista "bayooloji gudaha." SmartPharm waxay hadda horumarinaysaa novel, DNA-ku-xidhan antibody-ka monoclonal si looga hortago infekshanka SARS-CoV-2, fayraska sababa COVID-19 ee hoos yimaada qandaraas ay la gashay Hay'adda Mashaariicda Cilmi-baarista Sare ee Difaaca ee Wasaaradda Difaaca ee Mareykanka. SmartPharm waxa ay bilawday 2018 waxayna xarunteedu tahay Cambridge, MA, USA.

Caafimaadka Xoolaha Ark

Ark Animal Health waa shirkad ay iska leedahay Sorrento. Ark waxaa la sameeyay 2014 si loo keeno suuqa xoolaha ee saaxiibka ah xalal cusub oo laga soo saaray cilmi baarista aadanaha iyo hawlaha horumarinta Sorrento. Waxaa loo abaabulayaa si ay u noqoto urur si buuxda u madaxbannaan oo isku filan marka ay gaadho heerka ganacsiga (alaabta diyaar u ah in ay hesho oggolaanshaha FDA).

Barnaamijka horumarinta rasaasta ee Ark (ARK-001) waa hal dose resiniferatoxin (RTX) oo la isku duro oo nadiif ah. ARK-001 waxay heshay FDA CVM (Xarunta Daawada Xoolaha) MUMS (isticmaalka yar yar / noocyada yaryar) ee loogu talagalay xakameynta xanuunka kansarka lafaha ee eeyaha. Mashruucyada kale waxaa ka mid ah tilmaamo dheeraad ah oo loogu talagalay RTX meelaha sida xanuunka articular ee joogtada ah ee xayawaanka saaxiibka ah, xanuunka neuropathic ee fardaha, iyo cystitis idiopathic ee bisadaha, iyo sidoo kale sahaminta fursadaha horumarinta ee aagga cudurrada faafa ama daaweynta kansarka.

VirexHealth